CSF markers for pathogenic processes in Alzheimer’s disease: diagnostic implications and use in clinical neurochemistry
- 1 August 2003
- journal article
- review article
- Published by Elsevier in Brain Research Bulletin
- Vol. 61 (3) , 235-242
Abstract
No abstract availableKeywords
This publication has 54 references indexed in Scilit:
- Tau and apo E in CSFNeuroReport, 1999
- Cerebrospinal Fluid Tau Protein Levels in Demented and Nondemented AlcoholicsAlcohol, Clinical and Experimental Research, 1999
- Tau Protein in Cerebrospinal FluidAlzheimer Disease & Associated Disorders, 1998
- Longitudinal study of cerebrospinal fluid levels of tau, Aβ1–40, and Aβ1–42(43) in Alzheimer's disease: A study in JapanAnnals of Neurology, 1998
- Analysis of Heterogeneous βA4 Peptides in Human Cerebrospinal Fluid and Blood by a Newly Developed Sensitive Western Blot AssayJournal of Biological Chemistry, 1996
- Total tau protein immunoreactivity in lumbar cerebrospinal fluid of patients with Alzheimer's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1996
- Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's diseaseAnnals of Neurology, 1995
- Detection of Proteins in Normal and Alzheimer's Disease Cerebrospinal Fluid with a Sensitive Sandwich Enzyme‐Linked Immunosorbent AssayJournal of Neurochemistry, 1993
- Tau protein and the neurofibrillary pathology of Alzheimer's diseaseTrends in Neurosciences, 1993
- Clinical diagnosis of Alzheimer's diseaseNeurology, 1984